Radiodermatitis Market Size, Share and Global Trend By Product (Hydrogel & Hydrocolloid Dressing No-Sting Barrier Film,Silver Leaf Dressing, Silicone Coated Dressings, Corticosteroids, Hydrophilic Creams, Antibiotics, Honey Impregnated Gauze), By Route of Administration (Topical,Oral), By Distribution Channel (Hospitals, Cancer Specialist Clinics, Research Institutes, Others), and Regional Forecast, 2024-2032

Radiodermatitis is the skin condition observed in the patients undergoing radiation therapy used for the treatment of cancer or other skin conditions. The general symptoms associated with radiation burns include itching, redness, flaking, peeling, soreness, blisters, and others. Radiodermatitis can be either acute or chronic and can be categorized into four grades of severity, namely redness, peeling, swelling, and death of skin cells. Radiodermatitis can be very painful for cancer patients.

There are many oral medicines and ointments that are available for Radiodermatitis treatment. Hydrogel, silver lea and other types of dressing are also being used to treat radiodermatitis. In December 2016, Helsinn Healthcare SA received FDA approval for the use of Xonrid Gel, topical therapy for Radiodermatitis in the USA. Growing demand for effective treatment options further enhancing the quality of life patient is likely to boost the global Radiodermatitis market during the forecast period.

Growing investments in the research domain in developing effective therapies in the curing radiodermatitis and increasing incidences of radiodermatitis in cancer patients are likely to drive the growth of radiodermatitis market during the forecast period. In 2018, according to the World Health Organization (WHO), the total number of cancer cases in the world were around 18.1 million and is estimated to reach 29.5 million by 2040, further augmenting the growth of the global radiodermatitis market.

However, high risk of exposure to radiation to non-target areas because of which people tend to avoid radiation therapy is a major factor that can hinder the growth in global radiodermatitis market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global radiodermatitis market are 3M, Mölnlycke Health Care AB, KCI Licensing Inc., Smith & Nephew, Stratpharma AG, Helsinn Healthcare SA, and others.

SEGMENTATION

Among Route of administration segmentation, the topical segment is anticipated to hold the largest radiodermatitis market share during the forecast duration owing to the new product launches, ease of applications, and generating fast results. In July 2017, Stratpharma AG, a company specialized in manufacturing of topical products, launched StrataXRT a topical wound dressing for radiation dermatitis.

Key Insights

• Overview of Prevalence of Radiodermatitis


• Overview of Prevalence of cancer


• Pipeline Analysis


• Advancement in therapies for the treatment of radiodermatitis


• Recent industry developments such as partnerships, mergers, and acquisitions, etc.

Regional Analysis

The global radiodermatitis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the radiodermatitis market during the forecast period owing to the increase in the prevalence of cancer and the dominant use of radiation therapy as a treatment option for various types of cancer. According to the National Cancer Institute (NCI), in 2018, approximately 1,735,350 new cases of cancer were expected to be diagnosed in the U.S. which is likely to increase the demand for the therapies for the treatment of radiodermatitis. The growth of radiodermatitis market is likely to expand at a significant rate in the Asia Pacific region, due to the increasing government awareness programs educating about the available treatment options to cure dermatitis in cancer patients, and growing investments in improving healthcare infrastructure.

Key Industry Developments

• In July 2017, Stratpharma AG, a company specialized in manufacturing of topical products launched StrataXRT a topical wound dressing for radiation dermatitis.


• In December 2016, Helsinn Healthcare SA received FDA clearance for Xonrid Gel, topical therapy for radiodermatitis in the U.S.


• RepoCeuticals ApS, a pharmaceutical company in collaboration with Danish University Hospitals have initiated a clinical study on a skin cream for the treatment of radiation-induced dermatitis in a patient with breast cancer.